Please assess the completion status of the following clinical trial:

Trial Title: RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Participation in RE-LY, requires long term anticoagulation, provides written informed consent~Exclusion criteria:~Permanent discontinuation of dabigatran during RE-LY

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dabigatran dose 1 (Type: EXPERIMENTAL): dabigatran high dose twice daily
- dabigatran dose 2 (Type: EXPERIMENTAL): dabigatran low dose twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).